MétaCan
Menu
Back to cohort
Record W2159996784 · doi:10.1016/j.jalz.2010.05.1920

P3‐378: Misfolded superoxide dismutase 1 (SOD1) as a novel target for Alzheimer's disease

2010· article· en· W2159996784 on OpenAlexaff
Leslie I. Grad, James Donkin, Megan A. O’Neill, Jing Wang, Louise A. Scrocchi, Cheryl L. Wellington, Neil R. Cashman

Bibliographic record

VenueAlzheimer s & Dementia · 2010
Typearticle
Languageen
FieldMedicine
TopicCholinesterase and Neurodegenerative Diseases
Canadian institutionsAmorfix (Canada)Child and Family Research InstituteUniversity of British ColumbiaBC Research (Canada)
Fundersnot available
KeywordsSOD1EpitopeAmyotrophic lateral sclerosisAmyloid (mycology)Superoxide dismutaseCell biologyAlzheimer's diseaseChemistryBiologyNeuroscienceAntibodyImmunologyMedicineDiseasePathologyBiochemistryOxidative stress

Abstract

fetched live from OpenAlex

As the world population ages, the incidence of Alzheimer's disease (AD) is predicted to increase significantly, and so will the need for “disease-attenuating” therapeutics. A particularly promising approach is immunotherapy to remove abnormal and/or toxic proteins. To date, this approach has been directed solely against monomeric amyloid beta (Aβ), rather than misfolded aggregated Aβ or other proteins, with limited success. Therefore, alternative targets need to be identified for the rational development of AD therapeutics. To this end, we have found that misfolded superoxide dismutase 1 (SOD1) co-localizes with amyloid plaques in AD brain. Misfolded and/or oxidized SOD1 is known to be important in the etiology of amyotrophic lateral sclerosis (ALS), and its presence in AD suggests similar pathological mechanisms may pertain. We and others have found that SOD1 can switch from a soluble free radical defence enzyme to a net generator of reactive oxygen/nitrogen species as it misfolds. We theorized that portions of the molecule (disease-specific epitopes; DSEs) would be newly exposed on the molecular surface of misfolded/aggregated SOD1, but inaccessible on the natively-structured protein. We have verified this approach by developing specific monoclonal antibodies directed against several DSEs. Using DSE mAbs, misfolded SOD1 is detectable by immunoprecipitation in the hippocampus and frontal cortex of human AD brains, but not in those of aged-matched controls; misfolded SOD1 also co-localizes within amyloid plaques in brain tissue from AD patients by immunofluorescence and immunohistochemistry. Similarly, misfolded SOD1 can be immunoprecipitated from the brains of APP/PS1 transgenic mice, a well-studied model for AD, as early as 6 months, but not in non-transgenic littermates. Misfolded SOD1 is also immunofluorescently detectable in whole mouse brain. Our results clearly demonstrate the presence of misfolded SOD1 in the brains of both transgenic APP/PS1 mice and human AD patients, suggesting it as a novel AD marker. We will examine AD brains for the presence of misfolded SOD1-derived free radicals and determine the level of SOD1 aggregation; both characteristics contribute to ALS pathogenesis and may be relevant in AD. In vivo studies to address the therapeutic potential of antibodies and vaccines to misfolded SOD1 are ongoing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.311
Teacher spread0.275 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicCholinesterase and Neurodegenerative DiseasesFrench-language works237,207